- An estimated total of 30.3 million people have diabetes in the United States, a disease characterized by chronic elevation in blood glucose which over time, can lead to a host of health problems. Currently the most common types of diabetes are type 1, type 2, and gestational. The principal hormone of interest for diabetics is insulin, which is produced by the pancreas and allows glucose to be shuttled into our cells to be used for energy. When insulin sensitivity declines, or our body doesn’t make enough insulin, glucose stays in the blood and contributes to the pathogenesis of diabetes (Centers for Disease Control and Prevention, 2017). Particular interest in the essential nutrient chromium, an element that is found in the Earth’s crust and seawater, has shown slight promise in its ability to positively influence and affect blood glucose fluctuations. Chromium exists in varying forms and controversy in the scientific community still persists regarding the efficacy and usage of Chromium for diabetes management. In this study we tested the hypothesis of whether addition of chromium infused yeast or chromium picolinate to a high fat diet would confer a metabolic advantage in male C57BL/6J mice compared to mice that consumed a chromium-deficient high fat diet. Mice that were provided HF diets included control (HF) and two experimental diets, containing chromium picolinate (HF+ CrP) or chromium yeast (HF+ CrY). Animals were fed experimental diets ad libitum; body weight, glucose tolerance, insulin sensitivity, and organ weight ratios were measured. A glucose tolerance test showed Area Under the Curve (AUC) values were significantly lower in HF+CrP compared to HF+CrY. A subset of four groups were evaluated: LF, HF+Y, HF+CrP, HF+CrY. We demonstrated that chromium picolinate may confer a greater advantage than chromium yeast on some parameters related to metabolic syndrome.
- Key Words: diabetes, metabolic syndrome, chromium